A 12-year-old boy with a severe form of muscular dystrophy has said it is "cruel" that a new drug is not being made available ...

Duchenne muscular dystrophy (DMD) is a rare neurological condition that causes severe muscle weakness and intellectual disability. DMD is an inherited (passed down) disorder. The condition is ...

Muscular dystrophy is a disease caused by a genetic mutation. The muscles of muscular dystrophy patients weaken.. | Genetics ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new ...

Solid Biosciences' SGT-003 gene therapy showed strong dystrophin expression, muscle health improvements, and no serious safety concerns in early trial data.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...

I'm fighting a fatal disease that took the life of my brother. I work in biotech and know there are medical advances that ...

The trial was able to elicit more than double the microdystrophin gene in patients after 90 days of treatment.

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.